18/04/2024
Over 20 months, 447 patients presenting with a snakebite were included. One dose of Inoserp™ Pan-Africa (IPA) was administered to 361 patients and repeated at least once in 106 patients. No significant difference was shown between the proportion of adverse events in patients who received IPA (266/361, 73.7%) and those who did not (69/85, 81.2%) (p = 0.95). Adverse reactions, probably attributable to IPA, were identified in four (1.1%) patients, including one severe and three mild. All these reactions resolved favorably. None of the serious adverse events observed in twelve patients were attributed to IPA. No signs of late intolerance were observed in 302 patients.
https://www.linkedin.com/feed/update/urn:li:activity:7186802402702827520